Tender Details

Country: USA
Summary: Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (Amr) Infections, and Emerging Infectious Diseases
UST Ref No: 89980852
Deadline: 18 Oct 2023
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: 75N930
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Description
“Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections, and Emerging Infectious Diseases”
Request for Information (RFI)
Solicitation Number: HHS-NIH-NIAID-BAA2024-1
Introduction:
This is an RFI only and does not constitute a commitment, implied or otherwise, that the Department of Health and Human Services (DHHS), National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), will take procurement action in this matter. This is NOT a solicitation for proposals, applications, proposal abstracts or quotations. The purpose of this RFI is to obtain knowledge and information to assess the current “state of the science” in the field of vaccines. Further, neither DHHS/NIH/NIAID nor the government will be responsible for any cost incurred in furnishing this information.
Purpose:
This is a time-sensitive RFI, the purpose of which is to gather information on vaccine candidates in the areas identified below. This RFI is being issued for the purpose of obtaining knowledge and information for project planning and market research purposes.
Broadly protective coronavirus vaccines (BPCVs) that target beta-coronaviruses, provide durable protection and/or immunity (superior to licensed vaccines for SARS-CoV-2) as well as breadth of immunity (i.e., high titer binding and neutralizing antibodies against recently circulating SARS-CoV-2 Variants of Concern, and SARS-CoV-1) and utilize technology platforms that are suitable for rapid pandemic response. Vaccine candidates should incorporate novel immunogens or delivery platforms and must elicit mucosal immunity. Alphaviruses (excludes Chikungunya) Filoviruses: Sudan ebolavirus, Marburg virus, Bundibugyo virus, especially vaccine candidates that demonstrate efficacy after a single dose in a relevant animal model. Flaviviruses (except Zika, Dengue) Orthopoxviruses: next generation vaccines for smallpox suitable for all age...
Documents:

Request-for-Information--HHS-NIH-NIAID-BAA-2024-1.pdf

If you are registered member, kindly login to view full details of this tender notice:

Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (Amr) Infections, and Emerging Infectious Diseases - USA Tender

The HEALTH AND HUMAN SERVICES, DEPARTMENT OF, a Government sector organization in USA, has announced a new tender for Development of Vaccine Candidates for Biodefense, Antimicrobial Resistant (Amr) Infections, and Emerging Infectious Diseases. This tender is published on USARFP under UST Ref No: 89980852 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2023-10-18.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.